reports
- ABGSC Pulp & Paper Research
- Henrik Bartnes
- Martin Melbye
Novo Nordisk AS: 1 director
A director at Novo Nordisk AS sold 12,000 shares at 326.000DKK and the significance rating of the trade was 90/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearl...
Borregaard ASA: Reporting of transactions in Borregaard ASA's shares m...
Borregaard ASA: Reporting of transactions in Borregaard ASA's shares made by person discharging managerial responsibilities Borregaard's Board of Directors has issued 30,000 share options in relation to the CEO appointment. Reference is made to stock exchange release on 23 May 2025. The options will expire after five years (1 August 2030) and may be exercised in the last two years. The strike price of the options is NOK 219.31, based on the volume-weighted average share price (VWAP) over the last three trading days in July 2025 (29, 30 and 31 July), plus a 10% premium. The strike price wil...
Borregaard ASA: New CEO reinforces Borregaard’s commitment to speciali...
Borregaard ASA: New CEO reinforces Borregaard’s commitment to specialisation and value growth Tom Erik Foss-Jacobsen assumed his position as Borregaard’s new CEO on 1 August (see notice to Oslo Stock Exchange 23 May 2025). “Borregaard is well positioned with six production units, three R&D centres, and thirteen sales offices in key markets across Europe, the Americas, and Asia. We will continue to build on this solid foundation and our highly skilled organisation to advance our strategy of specialisation and value growth. Borregaard will continue to build on a strong legacy of specialisati...
Sobi Announces U.S. Food and Drug Administration Approves Doptelet® (a...
Sobi Announces U.S. Food and Drug Administration Approves Doptelet® (avatrombopag) for the Treatment of Thrombocytopenia in Pediatric Patients One Year and Older with Persistent or Chronic Immune Thrombocytopenia (ITP) Doptelet Sprinkle (avatrombopag) was approved as an effective formulation for children one year to less than six years. The primary endpoint was met in 27.8% of patients, confirming the efficacy in children and adolescents with persistent or chronic ITP WALTHAM, Mass., July 25, 2025 (GLOBE NEWSWIRE) -- Sobi North America, the North American affiliate of (Sobi®), today an...
Swedish Orphan Biovitrum AB: 1 director
A director at Swedish Orphan Biovitrum AB sold 7,723 shares at 288.474SEK and the significance rating of the trade was 66/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two y...
- ABGSC Healthcare Research
- Georg Tigalonov-Bjerke
- Morten Larsen
- ABGSC Pulp & Paper Research
- Henrik Bartnes
- Martin Melbye
- ABGSC Healthcare Research
- Georg Tigalonov-Bjerke
- Morten Larsen
- ABGSC Pulp & Paper Research
- Henrik Bartnes
- Martin Melbye
Borregaard ASA: EBITDA1 of NOK 522 million in the 2nd quarter
Borregaard ASA: EBITDA1 of NOK 522 million in the 2nd quarter Borregaard’s operating revenues increased to NOK 2,045 million (NOK 1,949 million)2 in the 2nd quarter of 2025. EBITDA1 reached NOK 522 million (NOK 510 million). The result in BioSolutions and BioMaterials increased while Fine Chemicals had a lower result. Continued growth in sales to agriculture was the main reason for the improved result in BioSolutions. In BioMaterials, the result increased due to higher sales prices, improved product mix and increased sales volume, partly offset by higher wood costs. Lower sales prices for b...
- ABGSC Healthcare Research
- Georg Tigalonov-Bjerke
- Morten Larsen
- Julia Sundvall
- Philip Ekengren
- ABGSC Capital Goods Research
- Martin Mauseth
- Simon Brun
- ABGSC Capital Goods Research
- Martin Mauseth
- Simon Brun
Borregaard ASA: Invitation to Q2 2025 announcement
Borregaard ASA: Invitation to Q2 2025 announcement 9 July 2025: Borregaard ASA (”Borregaard”, OSE ticker: BRG) Presentation of Q2 2025 results Borregaard will report second quarter 2025 results on Wednesday 16 July 2025 at 07:00 CEST. A stock exchange announcement will be made. A press release, the quarterly report and a presentation will be made available on . A presentation of the second quarter 2025 results will also be held at 08:30 CEST and can be followed live on web-TV at . It will be possible to ask questions via the web. All presentations will be held in English. For more info...
- ABGSC Investment Companies Research
- Derek Laliberté
- ABGSC Pulp & Paper Research
- Henrik Bartnes
- Martin Melbye
- ABGSC Pulp & Paper Research
- Henrik Bartnes
- Martin Melbye
- ABGSC Pulp & Paper Research
- Henrik Bartnes
- Martin Melbye
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.